6-ethyl-5-(n-propanoyl)-2(1H)-pyridinone | 88302-09-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-ethyl-5-(n-propanoyl)-2(1H)-pyridinone
• 英文别名: 6-Ethyl-5-propanoylpyridin-2(1H)-one；6-ethyl-5-propanoyl-1H-pyridin-2-one
• CAS: 88302-09-4
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: JMDUPPQVQZVCFS-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C
• 沸点：
  365.0±42.0 °C(Predicted)
• 密度：
  1.073±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(dimethylaminomethylene)heptane-3,5-dione 在 喹啉 、 氢氧化钾 、 铜 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 54.0h， 生成 6-ethyl-5-(n-propanoyl)-2(1H)-pyridinone
  参考文献：
  名称：

  结构上与强心药米力农相关的2-吡啶酮的合成和药理学表征。

  摘要：

  合成了以2-吡啶酮结构为特征的一类新型强心药。适当的sym-2-二甲基氨基亚甲基-1,3-二酮与氰基乙酸甲酯反应，得到所需化合物。评估了这些衍生物对豚鼠分离的心肌制剂引起强心反应的能力。化合物8b增加了心房收缩力，其程度显着高于用作参考化合物的母体药物米力农。在8b上进行的药理学表征和对接研究突出了其通过3型PDE（PDE3）抑制作用的选择性作用机理。

  DOI：

  10.1016/s0968-0896(03)00528-5

文献信息

• Process for preparing 5-(lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinone
  申请人：Sterling Drug Inc.

  公开号：US04412077A1

  公开（公告）日：1983-10-25

  4-R.sub.2 -5-(Lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones (I), useful as cardiotonics, where R.sub.2 is hydrogen or methyl, are prepared by reacting 2-(lower-alkanoyl)-1-(lower-alkyl)ethenamine (II) with lower-alkyl 2-propynoate or 2-butynoate respectively or by hydrolyzing 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinonitrile (III, Q is CN) or corresponding 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinamide to produce the corresponding 5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinic acid and decarboxylating said substituted nictotinic acid to produce I. Also disclosed and claimed are cardiotonic uses of 3-Q-4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones where Q is hydrogen or cyano and R.sub.2 is hydrogen or methyl (III). Also shown and claimed is methyl 4-acetyl-5-amino-2,4-hexadienoate or acid-addition salt thereof, useful as intermediate or cardiotonic.

  4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-2(1H)-吡啶酮(I)是一种有益的心力衰竭药物，其中R.sub.2为氢或甲基。该药物的制备方法是将2-(较低烷酰基)-1-(较低烷基)乙烯胺(II)分别与较低烷基2-丙炔酸酯或2-丁炔酸酯反应，或通过水解4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-1,2-二氢-2-氧基烟酰胺(III，其中Q为CN)或相应的4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-1,2-二氢-2-氧基烟酰胺产生相应的5-(较低烷酰基)-6-(较低烷基)-1,2-二氢-2-氧基烟酸，然后脱羧该取代烟酸产生I。此外，还揭示和声明了3-Q-4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-2(1H)-吡啶酮的心力衰竭用途，其中Q为氢或氰，R.sub.2为氢或甲基(III)。同时还显示和声明了4-乙酰基-5-氨基-2,4-己二烯酸甲酯或其酸盐加成物，可用作中间体或心力衰竭药物。
• 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their
  申请人：Sterling Drug Inc.

  公开号：US04524149A1

  公开（公告）日：1985-06-18

  4-R.sub.2 -5-(Lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones (I), useful as cardiotonics, where R.sub.2 is hydrogen or methyl, are prepared by reacting 2-(lower-alkanoyl)-1-(lower-alkyl)ethenamine (II) with lower-alkyl 2-propynoate or 2-butynoate respectively or by hydrolyzing 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinonitrile (III), Q is CN) or corresponding 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinamide to produce the corresponding 5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinic acid and decarboxylating said substituted nictotinic acid to produce I. Also disclosed and claimed are cardiotonic uses of 3-Q-4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones where Q is hydrogen or cyano and R.sub.2 is hydrogen or methyl (III). Also shown and claimed is methyl 4-acetyl-5-amino-2,4-hexadienoate or acid-addition salt thereof, useful as intermediate or cardiotonic.

  4-R.sub.2 -5-(低碳酰基)-6-(低烷基)-2(1H)-吡啶酮(I)是一种有益于心脏的强心剂，其中R.sub.2为氢或甲基，通过将2-(低碳酰基)-1-(低烷基)乙烯胺(II)分别与低烷基2-丙炔酸酯或2-丁炔酸酯反应或通过水解4-R.sub.2-5-(低碳酰基)-6-(低烷基)-1,2-二氢-2-氧基烟酰腈(III)(其中Q为CN)或相应的4-R.sub.2-5-(低碳酰基)-6-(低烷基)-1,2-二氢-2-氧基烟酰胺以产生相应的5-(低碳酰基)-6-(低烷基)-1,2-二氢-2-氧基烟酸，并脱羧化所述取代烟酸酸以产生I。还揭示和声明了3-Q-4-R.sub.2-5-(低碳酰基)-6-(低烷基)-2(1H)-吡啶酮的强心剂用途，其中Q为氢或氰，R.sub.2为氢或甲基(III)。还显示和声明了甲基4-乙酰基-5-氨基-2,4-己二烯酸酯或其酸盐加成物，可用作中间体或强心剂。
• Alkanoylpyridinones useful as cardiotonics and preparation thereof
  申请人：STERLING DRUG INC.

  公开号：EP0089022A2

  公开（公告）日：1983-09-21

  3-Q-4-R2-5-(Lower-alkanoyl)-6-(lower-alkyt)-2(1H)-pyridinones (I), useful as cardiotonics, where Q is hydrogen or cyano, R2 is hydrogen or methyl, are prepared by reacting 2-(lower-alkanoyl)-1-(lower-alkyl)ethenamine (II) with lower-alkyl 2-propynoate or 2-butynoate respectively or by hydrolyzing 4-R2-5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2- oxonicotinonitrile or corresponding 4-R2-5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinamide to produce the corresponding 5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotonic acid and decarboxylating said substituted nicotinic acid to produce I. Also shown and claimed is methyl 4-acetyl-5-amino-2,4-hexadienoate or acid-addition salt thereof, useful as intermediate or cardiontonic.

  3-Q-4-R2-5-(低级烷酰基)-6-(低级烷基)-2(1H)-吡啶酮 (I)，可用作强心剂，其中 Q 为氢或氰基，R2 为氢或甲基、分别通过 2-(低级烷酰基)-1-(低级烷基)乙烯胺 (II) 与低级烷基 2-丙炔酸酯或 2-丁炔酸酯反应，或通过水解 4-R2-5-(低级烷酰基)-6-(低级烷基)-1、或相应的 4-R2-5-(低级烷酰基)-6-(低级烷基)-1,2-二氢-2-氧代烟酰胺水解生成相应的 5-(低级烷酰基)-6-(低级烷基)-1,2-二氢-2-氧代烟酸，并将所述取代的烟酸脱羧生成 I。图中还显示并要求得到 4-乙酰基-5-氨基-2,4-己二烯酸甲酯或其酸加成盐，可用作中间体或心酮酸。
• Alkoxyimino ether derivatives of 5-acyl-2(1H)-pyridinones
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0140375A2

  公开（公告）日：1985-05-08

  This invention relates to alkoxyimino ether derivatives of 5-acyl-2(1H)-pyridinones and to their use as cardiotonic agents useful in treating cardiac failure, and to the process useful in the preparation thereof.

  本发明涉及 5-酰基-2(1H)-吡啶酮的烷氧基亚氨基醚衍生物，以及它们作为治疗心力衰竭的强心剂的用途和制备过程。
• LESHER, G. Y.;SINGH, BALDEV
  作者：LESHER, G. Y.、SINGH, BALDEV

  DOI：——

  日期：——